RELICITABINE 500 TAB

About

This medication is an orally administered fluoropyrimidine carbamate, functioning as a prodrug of 5-fluorouracil (5-FU). Its unique mechanism involves selective activation within tumor cells, where it is converted into the active cytotoxic agent, 5-FU, through a three-step enzymatic pathway. This targeted activation minimizes systemic exposure to 5-FU, potentially reducing systemic toxicity while maintaining robust anti-tumor efficacy. Once activated, 5-FU interferes with DNA synthesis and inhibits cell proliferation by inhibiting thymidylate synthase and being incorporated into RNA and DNA, ultimately leading to cell death. It is widely used in the treatment of various solid tumors, including metastatic colorectal cancer, adjuvant colorectal cancer, and metastatic breast cancer, offering a convenient oral chemotherapy option for patients.

Uses

• Metastatic colorectal cancer.
• Adjuvant colorectal cancer.
• Metastatic breast cancer.
• Advanced gastric cancer (off-label).

Directions For Use

Take orally with water within 30 minutes after a meal. Follow the prescribed dosage and schedule strictly.

Benefits

• Oral administration offers convenience.
• Targeted activation in tumor cells.
• Effective against various solid tumors.
• Can be used as monotherapy or in combination.
• Improved quality of life compared to IV chemotherapy.
• Reduced systemic toxicity profile.

Side Effects

• Hand-foot syndrome
• Diarrhea
• Nausea
• Vomiting
• Stomatitis (mouth sores)
• Fatigue
• Abdominal pain
• Myelosuppression (mild)
• Hyperbilirubinemia
• Dehydration
• Cardiac events (rare)
• Ocular toxicity (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol, as it may exacerbate gastrointestinal side effects.
• Pregnancy - Contraindicated due to potential for fetal harm; effective contraception is required during treatment.
• Breastfeeding - Not recommended; discontinue breastfeeding due to potential for serious adverse reactions in the infant.
• Liver - Use with caution; dose adjustments may be necessary in patients with hepatic impairment.
• Kidney - Dose adjustment is required for moderate to severe renal impairment; contraindicated in severe renal impairment.
• Lung - Monitor for new or worsening pulmonary symptoms; rare cases of interstitial pneumonitis reported.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.